In 2015, the US FDA Approved the Use of Secukinumab

Multiple Choice

In 2015, the US FDA approved the use of secukinumab for the treatment of psoriasis, a disease caused by chronic inflammation in the skin. Secukinumab is fully human monoclonal antibody against IL-17A. Clinical trials of this treatment indicated an increased rate of infections in patients on secukinumab, the majority of which were upper respiratory tract infections caused by viral or bacterial pathogens. For many of these infections, this side effect of secukinumab can be explained by:

A) Poor recruitment of neutrophils to infected airways
B) Lack of mucus production by airway epithelial cells
C) Poor recruitment of eosinophils to infected airways
D) Enhanced production of antimicrobial peptides by airway epithelial cells
E) Loss of tight junctions between airway epithelial cells